Genpact Supports embecta's Spin-Off into an Independent Diabetes Care Company
Genpact (NYSE: G) has been supporting embecta (Nasdaq: EMBC), a global diabetes care company, in its spin-off from Becton Dickinson and Company (BD) and its evolution as an independent leader in the diabetes technology market. Genpact's expertise in life sciences, healthcare, data, technology, and AI has enabled them to provide tailored solutions for embecta's needs.
The partnership has focused on modernizing embecta's operations, including implementing a robust ERP system, launching a standardized global operating model, and establishing end-to-end HR, finance, and procurement processes. This support has ensured uninterrupted customer service and supply chain stability, allowing embecta to continue providing insulin injection devices to 30 million people in over 100 countries.
Genpact (NYSE: G) ha supportato embecta (Nasdaq: EMBC), un'azienda globale di assistenza diabetica, nella sua separazione da Becton Dickinson and Company (BD) e nella sua evoluzione come leader indipendente nel mercato della tecnologia per il diabete. L'esperienza di Genpact nelle scienze della vita, nella sanità, nei dati, nella tecnologia e nell'IA ha permesso loro di fornire soluzioni su misura per le esigenze di embecta.
La partnership si è concentrata su la modernizzazione delle operazioni di embecta, compresa l'implementazione di un robusto sistema ERP, il lancio di un modello operativo globale standardizzato e l'istituzione di processi HR, finanziari e di approvvigionamento a ciclo completo. Questo supporto ha garantito un servizio clienti ininterrotto e stabilità nella catena di approvvigionamento, consentendo ad embecta di continuare a fornire dispositivi per iniezioni di insulina a 30 milioni di persone in oltre 100 paesi.
Genpact (NYSE: G) ha estado apoyando a embecta (Nasdaq: EMBC), una empresa global de atención al diabetes, en su escisión de Becton Dickinson and Company (BD) y su evolución como líder independiente en el mercado de la tecnología para diabéticos. La experiencia de Genpact en ciencias de la vida, atención médica, datos, tecnología e IA les ha permitido proporcionar soluciones personalizadas para las necesidades de embecta.
La asociación se ha centrado en modernizar las operaciones de embecta, incluyendo la implementación de un sistema ERP robusto, el lanzamiento de un modelo operativo global estandarizado y el establecimiento de procesos integrales de RRHH, finanzas y adquisiciones. Este apoyo ha asegurado un servicio al cliente ininterrumpido y la estabilidad de la cadena de suministro, permitiendo que embecta continúe proporcionando dispositivos de inyección de insulina a 30 millones de personas en más de 100 países.
Genpact (NYSE: G)은 전 세계 당뇨병 관리 회사인 embecta (Nasdaq: EMBC)의 Becton Dickinson and Company (BD)에서의 분사를 지원하고 당뇨 기술 시장의 독립적인 리더로 발전하는 데 도움을 주었습니다. Genpact의 생명 과학, 의료, 데이터, 기술 및 AI 분야의 전문성은 embecta의 필요에 맞춘 맞춤형 솔루션을 제공할 수 있게 해주었습니다.
파트너십은 embecta의 운영 현대화에 중점을 두었으며, 여기에는 강력한 ERP 시스템의 구현, 표준화된 글로벌 운영 모델의 출시, 인사, 재무 및 조달 프로세스의 종단간 수립이 포함됩니다. 이러한 지원은 중단 없는 고객 서비스와 공급망의 안정성을 보장하여 embecta가 100개국 이상에 3천만 명의 사람들에게 인슐린 주입 기기를 계속 제공할 수 있도록 했습니다.
Genpact (NYSE: G) a soutenu embecta (Nasdaq: EMBC), une entreprise mondiale de soins pour le diabète, dans sa scission de Becton Dickinson and Company (BD) et son évolution en tant que leader indépendant sur le marché de la technologie du diabète. Le savoir-faire de Genpact dans les sciences de la vie, la santé, les données, la technologie et l'IA leur a permis de proposer des solutions sur mesure pour les besoins d'embecta.
Le partenariat s'est concentré sur la modernisation des opérations d'embecta, y compris la mise en œuvre d'un système ERP robuste, le lancement d'un modèle opérationnel global standardisé et l'établissement de processus de gestion des ressources humaines, de finances et d'approvisionnements de bout en bout. Ce soutien a assuré un service client ininterrompu et une stabilité de la chaîne d'approvisionnement, permettant à embecta de continuer à fournir des dispositifs d'injection d'insuline à 30 millions de personnes dans plus de 100 pays.
Genpact (NYSE: G) hat embecta (Nasdaq: EMBC), ein globales Unternehmen für Diabetesversorgung, bei seiner Abspaltung von Becton Dickinson and Company (BD) unterstützt und bei seiner Entwicklung als unabhängiger Marktführer im Bereich Diabetestechnologie geholfen. Die Expertise von Genpact in den Bereichen Lebenswissenschaften, Gesundheitswesen, Daten, Technologie und KI hat es ihnen ermöglicht, maßgeschneiderte Lösungen für die Bedürfnisse von embecta bereitzustellen.
Die Partnerschaft hat sich auf die Modernisierung der Betriebsabläufe von embecta konzentriert, einschließlich der Implementierung eines robusten ERP-Systems, der Einführung eines standardisierten globalen Betriebsmodells und der Einrichtung umfassender HR-, Finanz- und Beschaffungsprozesse. Diese Unterstützung hat einen ununterbrochenen Kundenservice und eine stabile Lieferkette gewährleistet, sodass embecta weiterhin Insulininjektionsgeräte an 30 Millionen Menschen in über 100 Ländern liefern kann.
- Successful spin-off of embecta from BD, establishing it as an independent company
- Implementation of robust ERP system and standardized global processes
- Uninterrupted customer support and supply chain stability maintained
- Continuous provision of insulin injection devices to 30 million people in over 100 countries
- None.
Insights
The successful spin-off of embecta from Becton Dickinson and Company (BD) represents a significant milestone in the healthcare sector, particularly in the diabetes care market. As a Business Transformation Expert, I see several key implications:
- Market Dynamics: embecta's emergence as an independent entity could potentially lead to increased competition and innovation in the diabetes care space. This spin-off allows for more focused strategies and potentially faster decision-making processes.
- Operational Efficiency: The implementation of a robust ERP system and standardized global processes is important for embecta's long-term success. This modernization effort should result in improved operational efficiency, better resource allocation and enhanced ability to adapt to market changes.
- Supply Chain Resilience: Maintaining supply chain stability during such a significant transition is commendable. It demonstrates embecta's commitment to its
30 million customers across 100+ countries and showcases the company's operational strength. - Strategic Partnerships: The collaboration with Genpact highlights the importance of strategic partnerships in navigating complex business transformations. Leveraging external expertise in areas like data, technology and AI can accelerate growth and innovation.
While the spin-off presents opportunities, investors should closely monitor embecta's financial performance and market position as an independent entity in the coming quarters to assess its long-term viability and growth potential in the competitive diabetes care market.
As a Healthcare Industry Analyst, I find the spin-off of embecta from BD to be a noteworthy development in the diabetes care sector. Here are some critical points to consider:
- Market Focus: By becoming an independent entity, embecta can now concentrate exclusively on diabetes care technologies. This specialized focus could lead to more rapid innovation and potentially disruptive technologies in insulin delivery systems.
- Global Reach: With a presence in over 100 countries and serving
30 million people, embecta already has a substantial global footprint. This extensive reach provides a solid foundation for future growth and market expansion. - Industry Trends: The diabetes care market is experiencing significant growth due to increasing prevalence of diabetes worldwide. embecta's independence positions it to capitalize on this trend more effectively.
- Competitive Landscape: As a standalone company, embecta may face intensified competition from both established players and innovative startups. Its ability to innovate and differentiate its products will be important for maintaining and growing market share.
- Technological Integration: The partnership with Genpact, particularly in leveraging AI and data analytics, aligns with the broader trend of digital transformation in healthcare. This could potentially lead to more personalized and efficient diabetes management solutions.
Investors should keep a close eye on embecta's R&D investments, new product pipelines and its ability to maintain its market position as an independent entity. The company's financial performance in the coming quarters will be important in assessing its long-term prospects in the evolving diabetes care market.
Genpact's deep domain knowledge and data expertise enables embecta's vision to make a meaningful impact in the healthcare sector
"Genpact's deep expertise in the life sciences and healthcare sectors enables us to leverage extensive knowledge alongside our capabilities in data, technology, and AI. This combination allows us to drive positive outcomes and provide innovative solutions tailored to our clients' needs," said Balkrishan "BK" Kalra, President and CEO, Genpact. "Together, we are dedicated to realizing embecta's mission - to develop and provide solutions that make life better for people living with diabetes – and furthering Genpact's purpose: the relentless pursuit of a world that works better for people."
Genpact initially supported embecta's spin-off from BD and over time, the partnership has evolved to modernize embecta's operations. More specifically, Genpact supported the implementation of a robust ERP and launched an operating model with standardized global processes to meet the needs of a newly formed medical device company. Additionally, Genpact established end-to-end HR, finance, and procurement processes. This provided uninterrupted customer support and supply chain stability enabling embecta to continue providing insulin injection devices to 30 million people in more than 100 countries without interruption.
"From the beginning, our relationship was rooted in shared values and a commitment to mutual success," said Devdatt (Dev) Kurdikar, President and Chief Executive Officer, embecta. "Our seamless collaboration resulted in the successful transition of embecta to an independent entity, ensuring a continuous flow of goods and working capital, maintaining supply chain continuity, and providing critical support for our customers and the people they serve."
Visit here for more information about Genpact's work in the healthcare industry.
About Genpact
Genpact (NYSE: G) is a global professional services and solutions firm delivering outcomes that shape the future. Our 125,000+ people across 30+ countries are driven by our innate curiosity, entrepreneurial agility, and desire to create lasting value for clients. Powered by our purpose – the relentless pursuit of a world that works better for people – we serve and transform leading enterprises, including the Fortune Global 500, with our deep business and industry knowledge, digital operations services, and expertise in data, technology, and AI.
Get to know us at genpact.com and on LinkedIn, X, YouTube, and Facebook.
MEDIA CONTACT:
Siya Belliappa
Genpact Media Relations
+1 7185619843
Siya.belliappa@genpact.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/genpact-supports-embectas-spin-off-into-an-independent-diabetes-care-company-302208349.html
SOURCE Genpact Ltd.
FAQ
What support did Genpact provide for embecta's spin-off from BD?
How many countries does embecta (EMBC) serve with its insulin injection devices?
What is the focus of Genpact's partnership with embecta (EMBC)?
How many people use embecta's (EMBC) insulin injection devices?
